Biodistribution and Cellular Internalization of Inactivated SARS-CoV-2 in Wild-Type Mice.
Anett HudákGareth MorganJaromir BacovskyRoland PataiTamás F PolgárAnnamária LetohaAladar Pettko-SzandtnerCsaba VizlerLászló SzilákTamás LetohaPublished in: International journal of molecular sciences (2022)
Despite the growing list of identified SARS-CoV-2 receptors, the human angiotensin-converting enzyme 2 (ACE2) is still viewed as the main cell entry receptor mediating SARS-CoV-2 internalization. It has been reported that wild-type mice, like other rodent species of the Muridae family, cannot be infected with SARS-CoV-2 due to differences in their ACE2 receptors. On the other hand, the consensus heparin-binding motif of SARS-CoV-2's spike protein, PRRAR, enables the attachment to rodent heparan sulfate proteoglycans (HSPGs), including syndecans, a transmembrane HSPG family with a well-established role in clathrin- and caveolin-independent endocytosis. As mammalian syndecans possess a relatively conserved structure, we analyzed the cellular uptake of inactivated SARS-CoV-2 particles in in vitro and in vivo mice models. Cellular studies revealed efficient uptake into murine cell lines with established syndecan-4 expression. After intravenous administration, inactivated SARS-CoV-2 was taken up by several organs in vivo and could also be detected in the brain. Internalized by various tissues, inactivated SARS-CoV-2 raised tissue TNF-α levels, especially in the heart, reflecting the onset of inflammation. Our studies on in vitro and in vivo mice models thus shed light on unknown details of SARS-CoV-2 internalization and help broaden the understanding of the molecular interactions of SARS-CoV-2.
Keyphrases
- sars cov
- wild type
- respiratory syndrome coronavirus
- angiotensin converting enzyme
- angiotensin ii
- heart failure
- endothelial cells
- high fat diet induced
- single cell
- gene expression
- oxidative stress
- adipose tissue
- computed tomography
- mesenchymal stem cells
- transcription factor
- poor prognosis
- skeletal muscle
- metabolic syndrome
- low dose
- clinical practice
- bone marrow
- small molecule
- blood brain barrier
- induced pluripotent stem cells
- cerebral ischemia
- dna binding